Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Lintzeris

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
BMJ Open|July 22, 2018
LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependenceNadine Ezard, Adrian Dunlop, Michelle Hall, et al.
Journal of Addiction Medicine|June 3, 2024
Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, AustraliaNathan Heijstee, Eleanor Black, Emma Black, et al.
BMC Psychiatry|May 20, 2018
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocolAnjali K Bhardwaj, David J Allsop, Jan Copeland, et al.
The Medical Journal of Australia|July 14, 2023
Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort studyEmma Black, Raimondo Bruno, Kristie Mammen, et al.
The Lancet. Public Health|July 7, 2018
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort studyGabrielle Campbell, Wayne D Hall, Amy Peacock, et al.
Drug and Alcohol Review|October 7, 2024
Provider costs of treating opioid dependence with extended-release buprenorphine in AustraliaStella Settumba, Jeyran Shahbazi, Marianne Byrne, et al.
Drug and Alcohol Review|October 4, 2018
Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependenceSuzanne Nielsen, Nicholas Lintzeris, Bridin Murnion, et al.
Drug and Alcohol Review|December 16, 2022
Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019Emma Black, Kristie Mammen, Rachel M Deacon, et al.
BMC Psychiatry|March 3, 2024
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocolAnjali K Bhardwaj, Llew Mills, Michael Doyle, et al.
The International Journal on Drug Policy|March 4, 2025
Bridging the evidence and the politics: Implementation trial of supervised injectable opioid treatment (SIOT) in AustraliaAlison Ritter, James Bell, John Strang, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
BMJ Open|July 22, 2018
LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependenceNadine Ezard, Adrian Dunlop, Michelle Hall, et al.
Journal of Addiction Medicine|June 3, 2024
Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, AustraliaNathan Heijstee, Eleanor Black, Emma Black, et al.
BMC Psychiatry|May 20, 2018
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocolAnjali K Bhardwaj, David J Allsop, Jan Copeland, et al.
The Medical Journal of Australia|July 14, 2023
Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort studyEmma Black, Raimondo Bruno, Kristie Mammen, et al.
The Lancet. Public Health|July 7, 2018
Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort studyGabrielle Campbell, Wayne D Hall, Amy Peacock, et al.
Drug and Alcohol Review|October 7, 2024
Provider costs of treating opioid dependence with extended-release buprenorphine in AustraliaStella Settumba, Jeyran Shahbazi, Marianne Byrne, et al.
Drug and Alcohol Review|October 4, 2018
Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependenceSuzanne Nielsen, Nicholas Lintzeris, Bridin Murnion, et al.
Drug and Alcohol Review|December 16, 2022
Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019Emma Black, Kristie Mammen, Rachel M Deacon, et al.
BMC Psychiatry|March 3, 2024
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocolAnjali K Bhardwaj, Llew Mills, Michael Doyle, et al.
The International Journal on Drug Policy|March 4, 2025
Bridging the evidence and the politics: Implementation trial of supervised injectable opioid treatment (SIOT) in AustraliaAlison Ritter, James Bell, John Strang, et al.
Pageof 20